Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat in erythrocyte membranopathies and CDAII
NL-OMON58705Phase 2Recruiting
- Sponsor
- EuroBloodNet Association
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of mitapivat in erythrocyte membrane disorders and Congenital Dyserythropoietic Anemia Type 2, sponsored by EuroBloodNet Association. Primary endpoint: Safety of mitapivat. Started Mar 2024; status: recruiting.
02
Drugs
mitapivat
03
Conditions
erythrocyte membrane disordersCongenital Dyserythropoietic Anemia Type 2
Beyond the preview
Go deeper on NL-OMON58705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58705.